Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 43 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Small cell lung cancerThis series is part of our curated briefing on it.
- Samples
- 43 samples: 5 conditions, mostly with about 5 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE296261_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1258286. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 22 samples.
How we read this: 5 replicated groups read from 43 sample titles; they account for 22 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8966054 JHULX33_Empty_SAL1 JHULX33_Empty_SAL
- GSM8966055 JHULX33_Empty_SAL2 JHULX33_Empty_SAL
- GSM8966056 JHULX33_Empty_SAL3 JHULX33_Empty_SAL
- GSM8966057 JHULX33_Empty_SAL4 JHULX33_Empty_SAL
- GSM8966058 JHULX33_Empty_SAL5 JHULX33_Empty_SAL
- GSM8966059 JHULX33_USP22_SAL1 JHULX33_USP22_SAL
- GSM8966060 JHULX33_USP22_SAL2 JHULX33_USP22_SAL
- GSM8966061 JHULX33_USP22_SAL3 JHULX33_USP22_SAL
- GSM8966062 JHULX33_USP22_SAL4 JHULX33_USP22_SAL
- GSM8966063 JHULX33_USP22_SAL5 JHULX33_USP22_SAL
- GSM8966064 JHULX33_Empty_CE1 JHULX33_Empty_CE
- GSM8966065 JHULX33_Empty_CE2 JHULX33_Empty_CE
- GSM8966066 JHULX33_Empty _CE3
- GSM8966067 JHULX33_Empty_CE4 JHULX33_Empty_CE
- GSM8966068 JHULX33_Empty_CE5 JHULX33_Empty_CE
- GSM8966069 JHULX33_USP22_CE1 JHULX33_USP22_CE
- GSM8966070 JHULX33_USP22_CE2 JHULX33_USP22_CE
- GSM8966071 JHULX33_USP22_CE3 JHULX33_USP22_CE
- GSM8966072 JHULX33_USP22_CE4 JHULX33_USP22_CE
- GSM8966073 JHULX33_USP22_CE5 JHULX33_USP22_CE
- GSM8967722 FHSC14_IgG1 FHSC14_IgG
- GSM8967723 FHSC14_IgG2 FHSC14_IgG
- GSM8967724 FHSC14_IgG3 FHSC14_IgG
- GSM8967725 FHSC14_sgCtrl_SAL1_H3K27me3
- GSM8967726 FHSC14_sgCtrl_SAL2_H3K27me3
- GSM8967727 FHSC14_sgCtrl_SAL3_H3K27me3
- GSM8967728 FHSC14_sgUSP22_SAL1_H3K27me3
- GSM8967729 FHSC14_sgUSP22_SAL2_H3K27me3
- GSM8967730 FHSC14_sgUSP22_SAL3_H3K27me3
- GSM8967731 FHSC14_sgCtrl_CE1_H3K27me3
- GSM8967732 FHSC14_sgCtrl_CE2_H3K27me3
- GSM8967733 FHSC14_sgCtrl_CE3_H3K27me3
- GSM8967734 FHSC14_sgUSP22_CE1_H3K27me3
- GSM8967735 FHSC14_sgUSP22_CE2_H3K27me3
- GSM8967736 FHSC14_sgUSP22_CE3_H3K27me3
- GSM8967737 FHSC14_sgCtrl_SAL1_H2AK119ub
- GSM8967738 FHSC14_sgCtrl_SAL2_H2AK119ub
- GSM8967739 FHSC14_sgUSP22_SAL1_H2AK119ub
- GSM8967740 FHSC14_sgUSP22_SAL2_H2AK119ub
- GSM8967741 FHSC14_sgCtrl_CE1_H2AK119ub
+ 3 more — browse all 43 samples with per-sample file links →
- GSE296258 Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer [CUT&Tag] 23 samples same disease briefing · shares usp22, deubiquitylase, chemotherapy, resistance, confers, small, loss, lung
- GSE296155 Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer [RNA-seq] 20 samples same disease briefing · shares usp22, deubiquitylase, chemotherapy, resistance, confers, small, loss, lung
- GSE255095 An in vivo screening platform using PDX models reveals KEAP1, USP22 and other drivers of chemoresistance in small cell lung cancer 67 samples same disease briefing · shares usp22, resistance, small, lung
- GSE138474 Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer 43 samples same disease briefing · shares resistance, small, lung
- GSE297358 Loss of NOTCH2 Creates a TRIM28-Dependent Vulnerability in Small Cell Lung Cancer [ChIP-seq] 29 samples same disease briefing · shares small, loss, lung
- GSE297360 Loss of NOTCH2 Creates a TRIM28-Dependent Vulnerability in Small Cell Lung Cancer [human_bulk_RNA_seq] 14 samples same disease briefing · shares small, loss, lung
- GSE280212 Mechanisms of drugs-resistance in small cell lung cancer III 12 samples same disease briefing · shares resistance, small, lung
- GSE268219 Phase separation of RXRγ drives tumor chemoresistance and represents a therapeutic target for small cell lung cancer [RNA-Seq] 8 samples same disease briefing · shares resistance, small, lung
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.